The role of LEF1 in endometrial gland formation and carcinogenesis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Shelton, Dawne N ^a   Fornalik, Hubert ^a   Neff, Traci ^a   Park, Soo Yeun ^a   Bender, David ^a   DeGeest, Koen ^a   Liu, Xiaoming ^b   Xie, Weiliang ^b   Meyerholz, David K ^a   Engelhardt, John F ^b   Goodheart, Michael J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; LYMPHOID ENHANCER FACTOR 1; MATRILYSIN; RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; ESTRUS CYCLE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LYMPHOID ENHANCER FACTOR 1 GENE; MOUSE; NEWBORN; NONHUMAN; ONCOGENE; ORGANOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROUS CYCLE; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; METHYLNITROSOUREA; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; MIDDLE AGED;

MUS;

EID: 84863678911     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040312     Document Type: Article

References (55)

1. NCI website. Available:http://seer.cancer.gov/statfacts/html/corp.html. Accessed 2012 February 3.
2. Spencer TE, Carpenter KD, Hayashi K, Hu J, (2006) Branching Morphogenesis. Davies JA, editor. Georgetown: Landes Bioscience pp. 186-201.
3. Brody JR, Cunha GR, (1989) Histologic, morphometric, and immunocytochemical analysis of myometrial development in rats and mice: I. Normal development. Am J Anat 186: 1-20.
4. Gray CA, Bartol FF, Tarleton BJ, Wiley AA, Johnson GA, et al. (2001) Developmental biology of uterine glands. Biol Reprod 65: 1311-1323.
5. Evans GS, Gibson DF, Roberts SA, Hind TM, Potten CS, (1990) Proliferative changes in the genital tissue of female mice during the oestrous cycle. Cell Tissue Kinet 23: 619-635.
6. Putti R, Varano L, (1979) Histological and histochemical modifications of the uterine and vaginal mucosa of the mouse during the oestrus cycle. Basic Appl Histochem 23: 25-37.
7. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, et al. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787.
8. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, et al. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 96: 5522-5527.
9. Jung HC, Kim K, (2005) Identification of MYCBP as a beta-catenin/LEF-1 target using DNA microarray analysis. Life Sci 77: 1249-1262.
10. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T, (1999) beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155: 1033-1038.
11. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, et al. (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18: 2883-2891.
12. Nikaido T, Li SF, Shiozawa T, Fujii S, (1996) Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 78: 1248-1253.
13. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP, (2008) Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol 61: 36-42.
14. Bircan S, Ensari A, Ozturk S, Erdogan N, Dundar I, et al. (2005) Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol Oncol Res 11: 32-39.
15. Duan D, Yue Y, Zhou W, Labed B, Ritchie TC, et al. (1999) Submucosal gland development in the airway is controlled by lymphoid enhancer binding factor 1 (LEF1). Development 126: 4441-4453.
16. van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, et al. (1994) Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev 8: 2691-2703.
17. Machin P, Catasus L, Pons C, Munoz J, Matias-Guiu X, et al. (2002) CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 33: 206-212.
18. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, et al. (2002) Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 21: 7981-7990.
19. Konopka B, Janiec-Jankowska A, Czapczak D, Paszko Z, Bidzinski M, et al. (2007) Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J Cancer Res Clin Oncol 133: 361-371.
20. Tulac S, Nayak NR, Kao LC, Van Waes M, Huang J, et al. (2003) Identification, characterization, and regulation of the canonical Wnt signaling pathway in human endometrium. J Clin Endocrinol Metab 88: 3860-3866.
21. Mericskay M, Kitajewski J, Sassoon D, (2004) Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development 131: 2061-2072.
22. Miller C, Sassoon DA, (1998) Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 125: 3201-3211.
23. Whitten WK, Bronson FH, Greenstein JA, (1968) Estrus-inducing pheromone of male mice: transport by movement of air. Science 161: 584-585.
24. ImageJ website. Available:http://rsbweb.nih.gov/ij/. Accessed 2011 March 5.
25. Niwa K, Murase T, Furui T, Morishita S, Mori H, et al. (1993) Enhancing effects of estrogens on endometrial carcinogenesis initiated by N-methyl-N-nitrosourea in ICR mice. Jpn J Cancer Res 84: 951-955.
26. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, Hardisson D, Sarrio D, et al. (2003) Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22: 6115-6118.
27. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES, (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25: 1620-1628.
28. Wood GA, Fata JE, Watson KL, Khokha R, (2007) Circulating hormones and estrous stage predict cellular and stromal remodeling in murine uterus. Reproduction 133: 1035-1044.
29. Boras-Granic K, Chang H, Grosschedl R, Hamel PA, (2006) Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland. Dev Biol 295: 219-231.
30. Driskell RR, Goodheart M, Neff T, Liu X, Luo M, et al. (2007) Wnt3a regulates Lef-1 expression during airway submucosal gland morphogenesis. Dev Biol 305: 90-102.
31. Niwa K, Tanaka T, Mori H, Yokoyama Y, Furui T, et al. (1991) Rapid induction of endometrial carcinoma in ICR mice treated with N-methyl-N-nitrosourea and 17 beta-estradiol. Jpn J Cancer Res 82: 1391-1396.
32. Niwa K, Morishita S, Murase T, Mudigdo A, Tanaka T, et al. (1996) Chronological observation of mouse endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17 beta-estradiol. Cancer Lett 104: 115-119.
33. Kurman RJ, Ellenson LH, Ronnett BM, (2011) Blaustein's Pathology of the Female Genital Tract. New York: Springer Publishing. p 405.
34. Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF, (2002) Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. J Biol Chem 277: 33398-33410.
35. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, et al. (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28: 53-57.
36. Zysow BR, Kauser K, Lawn RM, Rubanyi GM, (1997) Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler Thromb Vasc Biol 17: 1741-1745.
37. Ray S, Xu F, Wang H, Das SK, (2008) Cooperative control via lymphoid enhancer factor 1/T cell factor 3 and estrogen receptor-alpha for uterine gene regulation by estrogen. Mol Endocrinol 22: 1125-1140.
38. Hai B, Yang Z, Millar SE, Choi YS, Taketo MM, et al. (2010) Wnt/beta-catenin signaling regulates postnatal development and regeneration of the salivary gland. Stem Cells Dev 19: 1793-1801.
39. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C, (1995) Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 9: 2364-2372.
40. Jesse S, Koenig A, Ellenrieder V, Menke A, (2010) Lef-1 isoforms regulate different target genes and reduce cellular adhesion. Int J Cancer 126: 1109-1120.
41. Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P, (1997) Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 57: 4624-4630.
42. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, et al. (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1792.
43. Simon M, Grandage VL, Linch DC, Khwaja A, (2005) Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 24: 2410-2420.
44. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, et al. (1998) Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 58: 3526-3528.
45. Baldus SE, Monig SP, Huxel S, Landsberg S, Hanisch FG, et al. (2004) MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 10: 2790-2796.
46. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, et al. (1999) beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155: 527-536.
47. Horst D, Kriegl L, Engel J, Jung A, Kirchner T, (2009) CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45: 2034-2040.
48. Horst D, Reu S, Kriegl L, Engel J, Kirchner T, et al. (2009) The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer 115: 2063-2070.
49. Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, et al. (2001) beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 10: 116-122.
50. Nei H, Saito T, Yamasaki H, Mizumoto H, Ito E, et al. (1999) Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog 25: 207-218.
51. Saegusa M, Hashimura M, Yoshida T, Okayasu I, (2001) beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 84: 209-217.
52. Saegusa M, Okayasu I, (2001) Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 194: 59-67.
53. Jeong JW, Lee HS, Franco HL, Broaddus RR, Taketo MM, et al. (2009) beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus. Oncogene 28: 31-40.
54. Kriegl L, Horst D, Reiche JA, Engel J, Kirchner T, et al. (2010) LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med 8: 123.
55. Yi YC, Chou PT, Chen LY, Kuo WH, Ho ES, et al. (2010) Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility. Clin Chem Lab Med 48: 337-344.